The genomics of dopamine agonists treatment of schizophrenia: a case of homozygous valine catecholo-methyltransferase polymorphism
The genomics of dopamine agonists treatment of schizophrenia: a case of homozygous valine catecholo-methyltransferase polymorphism
Author(s): Puja Patel, Vatsala Sharma, Tasmia Khan, George Letterio, Ravindi Gunasekara, Gurtej Singh Gill, Samuel Adeyemo, Heela Azizi, Jesslin Abraham, Olusegun Popoola, Chiedozie Ojimba, Karthik Cherukupally, Olaniyi Olayinka, Ayodele JolayemiSubject(s): Neuropsychology, Clinical psychology, Health and medicine and law
Published by: MedCrave Group Kft.
Keywords: We present the case of a patient with antipsychotics nonresponsive negative symptoms of Schizophrenia who responded significantly to a dopamine agonist within six days of treatment. He was previously
Summary/Abstract: We present the case of a patient with antipsychotics nonresponsive negative symptoms of Schizophrenia who responded significantly to a dopamine agonist within six days of treatment. He was previously unresponsive to other psychotropic medications. Genomic testing of the patient revealed a Homozygous Valine Catechol-O-Methyltransferase (COMT) polymorphism which is associated with high metabolism of dopamine in the frontal cortex with subsequent low dopamine activity. The significance of this finding for selecting good candidates for psychostimulant therapy for negative symptoms is discussed.
Journal: Journal of Psychology & Clinical Psychiatry
- Issue Year: 11/2020
- Issue No: 2
- Page Range: 66-70
- Page Count: 5
- Language: English
